undamentalytics Newsletter
Sign in

Urogen Pharma Ltd. income statement

In fiscal 2025, Urogen Pharma Ltd. reported revenue of $110m, up 21.4% on the year before, operating income of −$125m (a -113.7% margin) and net income of −$153m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue188101248648390110189
Cost of revenue012—158991217
Gross profit188−10114357738297171
Research and development—19374947485346576761
Selling, general and administrative———6090888393121155177
General and administrative6940————————
Operating income1−20−77−109−127−92−79−66−97−125−67
Income before tax−2−20−76−105−125−109−108−98−124−153−98
Income tax—00—312430−0
Net income−2−20−76−105−128−111−110−102−127−153−98
Diluted EPS−$0.48−$2.14−$4.80−$5.12−$5.90−$4.96————−$1.97
Diluted shares (average)9m10m16m21m22m22m23m29m43m48m49m
EBITDA1−20−77−109−126−91−78−65−96−125−66

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ABUS vs URGNURGN vs VALNNUVB vs URGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Urogen Pharma Ltd.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Urogen Pharma Ltd.